JANINE HYDEN: Open Payments
NPI 1982700464 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$910 in 49 payments from 11 companies in 2025. Trend: 2023 $813 · 2024 $822 · 2025 $910
Food & beverage: $910
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $293 |
| ABBVIE INC. | 8 | $140 |
| Madrigal Pharmaceuticals | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98 |
| One Lambda, Inc. | 1 | $79 |
| Genentech USA, Inc. | 2 | $46 |
| Mirum Pharmaceuticals, Inc. | 2 | $37 |
| Baxter Healthcare | 1 | $32 |
| La Jolla Pharmaceutical Company | 1 | $27 |
| ORPHALAN INC | 1 | $24 |
Products named: XIFAXAN, TEFLARO, REZDIFFRA, LIVTENCITY, Tecentriq, Livmarli, PERCLOT, GIAPREZA.
Industry payments across TX — which companies pay providers there.
